Erschienen in:
10.08.2023 | ASO Author Reflections
ASO Author Reflections: Menopausal Status Does Not Predict Successful Breast Conservation Surgery After Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma
verfasst von:
Kirithiga Ramalingam, MD, Rita Mukhtar, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 12/2023
Einloggen, um Zugang zu erhalten
Excerpt
The National Surgical Adjuvant Breast and Bowel Project (NSABP) B18 trial showed that neoadjuvant chemotherapy (NAC) for breast cancer significantly increased the rate of successful breast-conserving surgery with no detrimental impact on oncologic outcomes.
1 Since then, increased understanding of tumor biology has allowed for the selection of patients with tumors more likely to respond to such cytotoxic therapy. In addition to hormone receptor status, tumor histology and even menopausal status have been shown to influence rates of response to NAC. For patients with invasive lobular carcinoma (ILC), the second most common type of breast cancer, several studies show lower response rates to NAC and higher rates of mastectomy than those for invasive ductal carcinoma.
2 Because ILC is more likely to be diagnosed at an advanced stage than other types of breast cancer, there is a need to identify factors that make these tumors more amenable to BCS.
3 Some evidence shows that NAC may be more effective in pre-menopausal women than in post-menopausal women, but this has not been specifically studied in invasive lobular carcinoma (ILC).
4 The authors therefore addressed whether menopausal status played a role in successful breast-conserving surgery (BCS) after NAC) for patients with ILC. …
